David Dimmock, M.D., Joins Creyon Bio as Chief Medical Officer

SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., March 24, 2022 /PRNewswire/ — Creyon Bio, Inc. (“Creyon Bio”), a drug development company engineering RNA-based medicines and their components (oligonucleotide-based medicines or OBMs) with predictable safety and efficacy profiles, announced…

Click here to view original post